Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Last-Minute Changes To COVID Law A Good Compromise Says German IVD Industry

Executive Summary

Germany’s amended infection prevention law was voted through in the Bundestag after the COVID-19 testing frequency provision for hospital staff was made less onerous. But not everyone is happy.

You may also be interested in...



German Hospitals Say COVID Staff Testing ‘Madness’ Must Be Stopped

New COVID-19 winter protection rules in Germany, setting a daily testing requirement for hospital staff, represent a potentially massive extra burden for under-pressure providers, says the hospitals federation.

Putting The E In ESG: A Global Medtech’s Approach To Meeting The Climate Challenge

The pressures on global medtechs to focus more on sustainability are internal as well as external. Scope 3 adds yet another layer of compliance. Johnson & Johnson’s EMEA VP for Surgical Vision Erin McEachren explains to In Vivo how her organization meets these challenges while simultaneously addressing EU Medical Device Regulation requirements and ensuring patient safety standards.

Putting The E In ESG: The Provider’s View Of Sustainability Compliance

As the health care sector moves from linear to circular, medtechs, providers and patients all have roles to play in ensuring that current strategies, practices and behaviors contribute to guarantee a sustainable future. Part one of a short series on this theme looks as best practice for providers.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT145812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel